What is the maximum recommended dose of Lumify (brimonidine tartrate 0.025% ophthalmic solution) for adults and children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Lumify Maximum Dose

For adults and children 5 years and older, Lumify (brimonidine tartrate 0.025%) should not be used more than 4 times daily, with 1 drop instilled in the affected eye(s) per application 1.

Dosing Specifications

Adults and Children ≥5 Years

  • Frequency: Maximum 4 times daily
  • Dose per application: 1 drop in affected eye(s)
  • Formulation: Single-use vials (0.4 mL each) or multi-dose bottles
  • Administration: Discard single-use vials immediately after use; do not re-use 1

Children <5 Years

  • Not recommended: Consult a doctor before use 1
  • The FDA labeling does not provide dosing for this age group, indicating insufficient safety and efficacy data

Important Administration Guidelines

Contact lens wearers must remove lenses before instillation and wait at least 10 minutes before reinserting 1.

When using multiple ophthalmic products, wait at least 5 minutes between each product to prevent dilution and ensure proper absorption 1.

Clinical Context

The 4-times-daily maximum is based on clinical trials demonstrating:

  • Efficacy maintained for up to 8 hours per dose 2, 3
  • No tachyphylaxis (tolerance) with regular use over 4 weeks 2, 3
  • Minimal rebound redness upon discontinuation 2, 3
  • Excellent safety profile with infrequent adverse events 2

Exceeding the maximum dose of 4 times daily is not recommended as it has not been studied and may increase the risk of adverse effects without additional therapeutic benefit. The 8-hour duration of action supports the 4-times-daily dosing schedule as adequate for continuous redness relief throughout waking hours.

Critical Safety Note

This low-dose formulation (0.025%) is specifically for ocular redness relief and differs significantly from higher-concentration brimonidine formulations (0.15%, 0.2%) used for glaucoma treatment, which have different dosing schedules and indications.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.